Who is sponsoring NCT05623969?

NCT05623969 is sponsored by Assiut University.

What drugs are being tested in NCT05623969?

Interventions in NCT05623969: Holter ,Echo , Speckle tracking echocardiography.

What condition does NCT05623969 study?

NCT05623969 studies Atrial Cardiopathy.

Is NCT05623969 still recruiting?

NCT05623969 is currently status unknown. Last updated 30 November 2022.

Last reviewed 2022-11-30 · How we verify

NCT05623969

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Markers of Atrial Cardiopathay

Status unknown Last updated 30 November 2022

What this trial tests

trial testing Holter ,Echo , Speckle tracking echocardiography in Atrial Cardiopathy in 30 participants. Status unknown.

Timeline

30 November 2022

Primary endpoint
1 November 2025

1 November 2025

Quick facts

Lead sponsor	Assiut University
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	30
Start date	30 November 2022
Primary completion	1 November 2025
Estimated completion	1 November 2025
Sites	1 location across Egypt

Drugs / interventions tested

Holter ,Echo , Speckle tracking echocardiography

Conditions studied

Atrial Cardiopathy — all drugs for Atrial Cardiopathy →

Sponsor

Assiut University

Who can join

Adults 17 to 90, any sex, with Atrial Cardiopathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Marker of atrial cardiopathay as apredictor value of ischemic stroke

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Assiut University trials

Trials by the same sponsor.

NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05623969 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assiut University
Last refreshed: 30 November 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05623969.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing